ConductScience.org, home

Paper36922679

LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.

Malvi P and 7 others. Oncogene, 2023. Cited by 12 papers, by iCite.

Cite this record

ConductScience Library. LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition. Papers, record 36922679. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36922679

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
LIMK2 promotes melanoma tumor growth and metastasis through G3BP1-ESM1 pathway-mediated apoptosis inhibition.
PubMed
Journal
Oncogene
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
12
iCite
Relative citation ratio, by iCite
1.24
iCite
Revised in PubMed
2026-10-30
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Malvi PParmanandhttps://orcid.org/0000-0003-4101-5025
2Reddy DSDhana Sekhar
3Kumar RRaj
4Chava SSuresh
5Burela SSneha
6Parajuli KKeshab
7Zhang XXuchen
8Wajapeyee NNarendrahttps://orcid.org/0000-0003-3306-349X

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DNA HelicasesMajor topic
MelanomaMajor topic
Animals
Mice
Apoptosis
Lim Kinases
Poly-ADP-Ribose Binding Proteins
RNA Helicases
RNA Recognition Motif Proteins
Proteoglycans

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA013148NIH

Source NIH RePORTER

Download CSV of grants

References67

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
125589936Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.ACS Med Chem Lett2015https://conductscience.org/library/papers/25589936PubMed
210613909Cofilin phosphorylation and actin cytoskeletal dynamics regulated by rho- and Cdc42-activated LIM-kinase 2.J Cell Biol1999https://conductscience.org/library/papers/10613909PubMed
324509905Cofilin drives cell-invasive and metastatic responses to TGF-β in prostate cancer.Cancer Res2014https://conductscience.org/library/papers/24509905PubMed
435176431The roles of G3BP1 in human diseases (review).Gene2022https://conductscience.org/library/papers/35176431PubMed
518442402The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.BMC Med Genomics2008https://conductscience.org/library/papers/18442402PubMed
615728811EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med2005https://conductscience.org/library/papers/15728811PubMed
724265155Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.Cancer Discov2014https://conductscience.org/library/papers/24265155PubMed
828581515GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis.Oncogene2017https://conductscience.org/library/papers/28581515PubMed
925932675Targeting cancer with kinase inhibitors.J Clin Invest2015https://conductscience.org/library/papers/25932675PubMed
1034568836Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.Nat Cancer2021https://conductscience.org/library/papers/34568836PubMed
1134212149Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.RSC Chem Biol2021https://conductscience.org/library/papers/34212149PubMed
1228407145GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses.Nucleic Acids Res2017https://conductscience.org/library/papers/28407145PubMed
1334795264G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer.Nat Commun2021https://conductscience.org/library/papers/34795264PubMed
1430259761A comprehensive review of protein kinase inhibitors for cancer therapy.Expert Rev Anticancer Ther2018https://conductscience.org/library/papers/30259761PubMed
1530207743The roles and mechanisms of G3BP1 in tumour promotion.J Drug Target2019https://conductscience.org/library/papers/30207743PubMed
1621447797Resistance to MEK inhibitors: should we co-target upstream?Sci Signal2011https://conductscience.org/library/papers/21447797PubMed
1734002056Kinase drug discovery 20 years after imatinib: progress and future directions.Nat Rev Drug Discov2021https://conductscience.org/library/papers/34002056PubMed
1831734559Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer.Mol Ther Nucleic Acids2019https://conductscience.org/library/papers/31734559PubMed
1934109132Targeting Endothelial Cell-Specific Molecule 1 Protein in Cancer: A Promising Therapeutic Approach.Front Oncol2021https://conductscience.org/library/papers/34109132PubMed
2018505921Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases.Mol Cancer Res2008https://conductscience.org/library/papers/18505921PubMed

See all 67 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMIDTitleJournalYearIn PapersSource
42066056Discovery and Development of a Potent LIMK2 Isoform-Specific Degrader.ACS Chem Biol2026https://conductscience.org/library/papers/42066056PubMed
42007146Banxia Xiexin Decoction inhibits chemoresistance in gastric cancer by regulating BMSC-derived exosome-mediated G3BP1-YWHAZ protein interaction.Am J Transl Res2026https://conductscience.org/library/papers/42007146PubMed
40775397LIMK2 promotes centrosome clustering and cancer progression by activating MST4-mediated phosphorylation of NPM1.Oncogene2025https://conductscience.org/library/papers/40775397PubMed
39361252Regulation and signaling of the LIM domain kinases.Bioessays2025https://conductscience.org/library/papers/39361252PubMed
39281564The role of ESM1 in the lipids metabolic reprogramming and angiogenesis of lung adenocarcinoma cells.Heliyon2024https://conductscience.org/library/papers/39281564PubMed
39100690Stress granules in cancer: Adaptive dynamics and therapeutic implications.iScience2024https://conductscience.org/library/papers/39100690PubMed
37141984LIMK2: A Multifaceted kinase with pleiotropic roles in human physiology and pathologies.Cancer Lett2023https://conductscience.org/library/papers/37141984PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
LIMK23985PubTator's text mininghttps://conductscience.org/library/genes/3985

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36922679

GET https://conductscience.org/api/papers/v1/36922679/references?page=2